gip vs glp 1 Targeting GLP-1, & GCG in Obesity and Type 2 Diabetes Research GIP Receptor Agonism Attenuates GLP-1

In clinical trials, semaglutide at 0.4 mg daily led to an average 13% reduction in body weight

A large meta-analysis of 66 RCTs found curcumin/turmeric supplementation significantly reduced levels of inflammatory markers, including C-reactive protein, tumor necrosis factor, and interleukin-6, and improved antioxidant activity compared to placebo [86]

8 p.m

The future directions and challenges of new small-molecule GLP-1R agonists, such as danuglipron, are multifaceted

For the pharmacokinetics studies performed by TechMedILL service (PCBIS platform, CNRS UMS3286), mice were housed in polycarbonate cages (PCT2L12SHT, Allentown) enriched with play tunnels throughout the experimental phase

Human evidence - Phase 2 MASLD substudy (Sanyal et al., Nature Medicine 2024) Adults with MASLD and at least 10% liver fat